Trial Profile

A Phase 1/2 safety and efficacy trial for exebacase as a treatment for patients with chronic post-operative Staphylococcal prosthetic joint infections of knee

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Aug 2023 According to a ContraFect media release, Garrett Nichols, MD, Interim Chief Medical Officer of company, will discuss data supporting the study of Exebacase in this phase 1/2 trial for CF-370 at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.
27 Jun 2023 According to a ContraFect media release, the proceeds to the company from the exercise of the existing warrants are $9.6 million that will be used to support ongoing enrollment in this trial.
15 May 2023 According to a ContraFect media release, first patient dosed at the Hospices Civils de Lyon in Lyon, France, the clinical site where the study is being conducted.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com